Apellis Pharmaceuticals Inc (NAS:APLS)
$ 39.68 -3.92 (-8.99%) Market Cap: 4.82 Bil Enterprise Value: 5.07 Bil PE Ratio: 0 PB Ratio: 18.04 GF Score: 38/100

Apellis Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript

Sep 16, 2022 / 08:55AM GMT
Release Date Price: $62.56 (-3.38%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

Thank you, everybody. Hopefully, you can hear me. Good morning. Welcome to be Bank of America Healthcare Conference line from London. I'm Tazeen Ahmad. I'm one of the biotech analysts here at the firm. It is my pleasure to have our next presenting company. Sitting here with me this morning are 3 members from Apellis, CEO, Cedric Francois; Chief Commercial Officer, Adam Townsend; Chief Financial Officer, Tim Sullivan. Good morning, gentlemen and thank you for making the trip over.

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Good morning. Thank you. Happy to be here.

Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

So I think everyone else is saying is familiar with the company so we can skip over the intro and go straight to, I think, the main questions.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot